T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

[1]  A. Hemminki.  Oncolytic Immunotherapy: Where Are We Clinically? , 2014, Scientifica.

[2]  K. Partanen,et al.  [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. , 2013, Human gene therapy.

[3]  D. Linehan,et al.  Targeting tumor-infiltrating macrophages to combat cancer. , 2013, Immunotherapy.

[4]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[5]  A. Hemminki,et al.  Oncolytic Virotherapy Trials—Letter , 2013, Clinical Cancer Research.

[6]  G. Coukos,et al.  Deciphering and reversing tumor immune suppression. , 2013, Immunity.

[7]  S. Ramakrishna,et al.  Immune system: a double-edged sword in cancer , 2013, Inflammation Research.

[8]  L. Zitvogel,et al.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists , 2013, Cell Death and Differentiation.

[9]  A. Salazar,et al.  Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy , 2013, The Journal of Immunology.

[10]  K. Partanen,et al.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  K. Partanen,et al.  Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus , 2013, Clinical Cancer Research.

[12]  A. Hemminki,et al.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  A. Godkin,et al.  T cell subsets and colorectal cancer: discerning the good from the bad. , 2012, Cellular immunology.

[14]  N. Senzer,et al.  Oncolytic viruses for induction of anti-tumor immunity. , 2012, Current pharmaceutical biotechnology.

[15]  A. Eliopoulos,et al.  Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. , 2012, Cancer research.

[16]  L. Montanaro,et al.  Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. , 2012, Cancer research.

[17]  L. Rivoltini,et al.  Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients , 2012, Cancer Immunology, Immunotherapy.

[18]  S. K. Watkins,et al.  Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells , 2012, Cancer Immunology, Immunotherapy.

[19]  M. Linnebacher,et al.  Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. , 2011, International journal of oncology.

[20]  C. Mackay,et al.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. , 2011, Cancer research.

[21]  B. Bonnotte,et al.  The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance , 2011, Clinical & developmental immunology.

[22]  I. Ellis,et al.  Tumour-infiltrating macrophages and clinical outcome in breast cancer , 2011, Journal of Clinical Pathology.

[23]  K. Partanen,et al.  Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[25]  J. Gui,et al.  Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. , 2011, Neuro-oncology.

[26]  C. Yun,et al.  Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα , 2011, Gene Therapy.

[27]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[28]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[29]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[30]  K. Partanen,et al.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Ristimäki,et al.  Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. , 2010, Cancer research.

[33]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[34]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[35]  Y. Liu,et al.  In situ adenovirus vaccination engages T effector cells against cancer. , 2009, Vaccine.

[36]  K. Aozasa,et al.  Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. , 2009, The Journal of urology.

[37]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[38]  J. Mymryk,et al.  Intrinsic Structural Disorder in Adenovirus E1A: a Viral Molecular Hub Linking Multiple Diverse Processes , 2008, Journal of Virology.

[39]  J. Rodgers,et al.  Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  P. Dahm,et al.  Reversal of Tumor-Mediated Immunosuppression , 2007, Clinical Cancer Research.

[41]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[42]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[43]  R. Alemany,et al.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.